Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (32)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kim, D. Y.
Right arrow Articles by Kim, N. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, D. Y.
Right arrow Articles by Kim, N. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:383-387, 2003
© 2003 European Society for Medical Oncology

Original Paper

Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer

D. Y. Kim, J. H. Kim, S.-H. Lee, T. Y. Kim, D. S. Heo+, Y.-J. Bang and N. K. Kim

Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

Received 3 June 2002; revised 23 September 2002; accepted 22 October 2002

Background:

Oxaliplatin shows preclinical activity in many cancer cell lines that are resistant to cisplatin, and also has synergism with 5-fluorouracil (5-FU). We undertook this study to evaluate the efficacy and toxicities of a combined oxaliplatin, 5-FU and leucovorin (LV) continuous infusion regimen in patients with advanced gastric cancer who progressed during or after treatment with 5-FU and platinum compounds.

Patients and methods:

Twenty-six patients with advanced gastric cancer, whose disease progressed while receiving, or after discontinuing, chemotherapy with a 5-FU and platinum regimen, were enrolled in this study. Treatment comprised oxaliplatin (85 mg/m2 on day 1) as a 2-h infusion followed by bolus 5-FU (400 mg/m2 on day 1), and 48-h infusion of 5-FU 2.4–3.0 g/m2 concurrently with LV 150 mg/m2. Cycles were repeated at 2-week intervals.

Results:

Of the 23 evaluable patients, there were six partial responses (response rate 26%). All responding patients were among those who entered into this trial immediately after failure of previous chemotherapy with 5-FU and cisplatin. The median time to progression was 4.3 months and the median overall survival was 7.3 months. The most common hematologic toxicity was grade 1–2 anemia in 39 cycles (39%). No grade 4 leukopenia or thrombocytopenia were observed. The most common non-hematologic toxicity was nausea/vomiting (33%). Peripheral neuropathy of grade 1 or 2 was noted (27%), but there was no grade 3 or 4 neurotoxicity.

Conclusions:

This phase II study of oxaliplatin, 5-FU and LV continuous infusion showed activity in previously platinum-treated patients with advanced gastric cancer, with acceptable toxicities.

Key words: advanced gastric cancer, 5-fluorouracil, leucovorin, oxaliplatin, phase II study, platinum compounds


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
J. Jeong, H.-C. Jeung, S. Y. Rha, C. K. Im, S. J. Shin, J. B. Ahn, S. H. Noh, J. K. Roh, and H. C. Chung
Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
Ann. Onc., June 1, 2008; 19(6): 1135 - 1140.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S.-E. Al-Batran, J. T. Hartmann, S. Probst, H. Schmalenberg, S. Hollerbach, R. Hofheinz, V. Rethwisch, G. Seipelt, N. Homann, G. Wilhelm, et al.
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
J. Clin. Oncol., March 20, 2008; 26(9): 1435 - 1442.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Richards, D. McCollum, L. Wilfong, M. Sborov, K. A. Boehm, F. Zhan, and L. Asmar
Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction
Ann. Onc., January 1, 2008; 19(1): 104 - 108.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H-C Kwon, M. Roh, S. Oh, S-H Kim, M. Kim, J-S Kim, and H-J Kim
Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer
Ann. Onc., March 1, 2007; 18(3): 504 - 509.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S.-E. Al-Batran, A. Atmaca, S. Hegewisch-Becker, D. Jaeger, S. Hahnfeld, M. J Rummel, G. Seipelt, A. Rost, J. Orth, A. Knuth, et al.
Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric Cancer
J. Clin. Oncol., February 15, 2004; 22(4): 658 - 663.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J. H. Chun, H. K. Kim, J. S. Lee, J. Y. Choi, H. G. Lee, S. M. Yoon, I. J. Choi, K. W. Ryu, Y.-W. Kim, and J.-M. Bae
Weekly Irinotecan in Patients with Metastatic Gastric Cancer Failing Cisplatin-based Chemotherapy
Jpn. J. Clin. Oncol., January 1, 2004; 34(1): 8 - 13.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.